Host innate immune responses to microbial pathogens

Current Vascular Pharmacology

Volumn 11, Issue 2, 2013, Pages 123-132

  Delaloye, Julie ^a   Calandra, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

C type lectin receptors; Cytokine; Innate immunity; Nucleotide binding oligomerization domain like receptors; Pattern recognition receptors; RIG I like receptors; Sepsis; Toll like receptors

Indexed keywords

COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT COMPONENT C4A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT RECEPTOR; ERITORAN; INTERLEUKIN 17; LECTIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PLACEBO; PROLYLLEUCYLGLYCINAMIDE; RETINOIC ACID INDUCIBLE PROTEIN I; SCAVENGER RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; COMPLEMENT SYSTEM; GRAM NEGATIVE BACTERIUM; HEART FAILURE; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; LOW DRUG DOSE; MORBIDITY; MORTALITY; NEUTROPHIL; PHASE 2 CLINICAL TRIAL (TOPIC); SEPSIS; STIMULUS; TRANSLATIONAL RESEARCH; ANIMAL; BACTEREMIA; HISTORY; IMMUNOLOGY; MICROBIOLOGY; MYCOSIS;

ANIMALS; BACTEREMIA; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MYCOSES; RECEPTORS, PATTERN RECOGNITION; SEPSIS;

EID: 84875326334     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311020002     Document Type: Article

References (172)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-54.
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10.
3. Angus DC, Pereira CA, Silva E. Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets 2006; 6:207-12.
4. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140:805-20.
5. Medzhitov R. Innate immunity: quo vadis? Nat Immunol 2010; 11:551-3.
6. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34:637-50.
7. Rehwinkel J, Reis e Sousa C. RIGorous detection: exposing virus through RNA sensing. Science 2010; 327:284-6.
8. Maekawa T, Kufer TA, Schulze-Lefert P. NLR functions in plant and animal immune systems: so far and yet so close. Nat Immunol 2011; 12:817-26.
9. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327:291-5.
10. Dinarello CA. Historical insights into cytokines. Eur J Immunol 2007; 37 (Suppl 1):S34-45.
11. Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med 2011; 208:2581-90.
12. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785-97.
13. Wallis R, Mitchell DA, Schmid R, et al. Paths reunited: Initiation of the classical and lectin pathways of complement activation. Immunobiology 2010; 215:1-11.
14. Hack CE, Nuijens JH, Felt-Bersma RJ, et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989; 86:20-6.
15. Ward PA. The harmful role of c5a on innate immunity in sepsis. J Innate Immun 2010; 2:439-45.
16. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8:776-87.
17. Ward PA. Role of C5 activation products in sepsis. ScientificWorldJournal 2010; 10:2395-402.
18. Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med 1999; 5:788-92.
19. Riedemann NC, Guo RF, Hollmann TJ, et al. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J 2004; 18:370-2.
20. Guo RF, Huber-Lang M, Wang X, et al. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest 2000; 106:1271-80.
21. Niederbichler AD, Hoesel LM, Westfall MV, et al. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med 2006; 203:53-61.
22. Nuijens JH, Eerenberg-Belmer AJ, Huijbregts CC, et al. Proteolytic inactivation of plasma C1-inhibitor in sepsis. J Clin Invest 1989; 84:443-50.
23. Dorresteijn MJ, Visser T, Cox LA, et al. C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia. Crit Care Med 2010; 38:2139-45.
24. Silasi-Mansat R, Zhu H, Popescu NI, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 2010; 116:1002-10.
25. Rock FL, Hardiman G, Timans JC, et al. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998; 95:588-593.
26. Hoffmann JA, Reichhart JM. Drosophila innate immunity: an evolutionary perspective 1. Nat Immunol 2002; 3:121-126.
27. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008; 226:10-8.
28. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-84.
29. Hacker H, Tseng PH, Karin M. Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol 2011; 11:457-68.
30. Jenkins KA, Mansell A. TIR-containing adaptors in Toll-like receptor signalling. Cytokine 2010; 49:237-44.
31. Reizis B, Bunin A, Ghosh HS, et al. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol 2011; 29:163-83.
32. Tabeta K, Hoebe K, Janssen EM, et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 2006; 7:156-164.
33. Takahashi K, Shibata T, Akashi-Takamura S, et al. A protein associated with Toll-like receptor (TLR) 4 (PRAT4A) is required for TLR-dependent immune responses. J Exp Med 2007; 204:2963-2976.
34. Kawasaki T, Kawai T, Akira S. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol Rev 2011; 243:61-73.
35. Saitoh T, Satoh T, Yamamoto N, et al. Antiviral protein Viperin promotes Toll-like receptor 7-and Toll-like receptor 9-mediated type I interferon production in plasmacytoid dendritic cells. Immunity 2011; 34:352-63.
36. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434:772-7.
37. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-2088.
38. Underhill DM, Ozinsky A, Hajjar AM, et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999; 401:811-815.
39. Ozinsky A, Underhill DM, Fontenot JD, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000; 97:13766-13771.
40. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099-103.
41. Kurt-Jones EA, Chan M, Zhou S, et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci USA 2004; 101:1315-20.
42. Bieback K, Lien E, Klagge IM, et al. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol 2002; 76:8729-8736.
43. Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-1531.
44. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526-1529.
45. Lund JM, Alexopoulou L, Sato A, et al. Recognition of singlestranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004; 101:5598-5603.
46. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-738.
47. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-745.
48. Hedayat M, Netea MG, Rezaei N. Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. Lancet Infect Dis 2011; 11:702-12.
49. Shimazu R, Akashi S, Ogata H, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189:1777-82.
50. Nagai Y, Akashi S, Nagafuku M, et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002; 3:667-72.
51. Roger T, Froidevaux C, Le Roy D, et al. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci USA 2009; 106:2348-52.
52. Daubeuf B, Mathison J, Spiller S, et al. TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol 2007; 179:6107-14.
53. Spiller S, Elson G, Ferstl R, et al. TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J Exp Med 2008; 205:1747-54.
54. Rossignol DP, Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res 2002; 8:483-8.
55. Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem 2004; 4:1147-71.
56. Mullarkey M, Rose JR, Bristol J, et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003; 304:1093-102.
57. Lien E, Chow JC, Hawkins LD, et al. A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/tolllike receptor 4 signaling pathway. J Biol Chem 2001; 276:1873-80.
58. Kim HM, Park BS, Kim JI, et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007; 130:906-17.
59. Tidswell M, Tillis W, Larosa SP, et al. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010; 38:72-83.
60. Matsuyama K. Eisai's sepsis drug eritoran fails to save more lives in final-stage study. Bloomberg Web site. Posted January 25, 2011. Accessed November 18, 2011.:http://www.bloomberg.com/news/2011-01-25/eisai-s-sepsis-drug-eritoran-fails-to-save-more-lives-infinal-stage-study.html.
61. Ii M, Matsunaga N, Hazeki K, et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits tolllike receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 2006; 69:1288-95.
62. Alves-Filho JC, Freitas A, Souto FO, et al. Regulation of chemokine receptor by Toll-like receptor 2 is critical to neutrophil migration and resistance to polymicrobial sepsis. Proc Natl Acad Sci USA 2009; 106:4018-23.
63. Vallejo JG. Role of toll-like receptors in cardiovascular diseases. Clin Sci (Lond) 2011; 121:1-10.
64. Fallach R, Shainberg A, Avlas O, et al. Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. J Mol Cell Cardiol 2010; 48:1236-44.
65. Zhu X, Bagchi A, Zhao H, et al. Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction. Crit Care Med 2007; 35:886-92.
66. Rolli J, Rosenblatt-Velin N, Li J, et al. Bacterial flagellin triggers cardiac innate immune responses and acute contractile dysfunction. PLoS One 2010; 5:e12687.
67. Franchi L, Warner N, Viani K, Nunez G. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 2009; 227:106-28.
68. Elinav E, Strowig T, Henao-Mejia J, Flavell RA. Regulation of the antimicrobial response by NLR proteins. Immunity 2011; 34:665-79.
69. Hsu YM, Zhang Y, You Y, et al. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat. Immunol. 2007; 8:198-205.
70. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. Journal of Biological Chemistry 2003; 278:8869-8872.
71. Werts C, Rubino S, Ling A, et al. Nod-like receptors in intestinal homeostasis, inflammation, and cancer. J Leukoc Biol 2011; 90:471-82.
72. Vignal C, Singer E, Peyrin-Biroulet L, et al. How NOD2 mutations predispose to Crohn's disease? Microbes. Infect. 2007; 9:658-663.
73. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev 2011; 243:136-51.
74. Burckstummer T, Baumann C, Bluml S, et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009; 10:266-72.
75. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature 2012; 481:278-86.
76. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10:417-426.
77. Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1betaprocessing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004; 20:319-325.
78. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241.
79. Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440:228-232.
80. Dostert C, Petrilli V, Van BR, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320:674-677.
81. Petrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007; 19:615-622.
82. Eisenbarth SC, Colegio OR, O'Connor W, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453:1122-1126.
83. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008; 9:857-865.
84. Franchi L, Amer A, Body-Malapel M, et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat. Immunol. 2006; 7:576-582.
85. Lightfield KL, Persson J, Brubaker SW, et al. Critical function for Naip5 in inflammasome activation by a conserved carboxyterminal domain of flagellin. Nat Immunol 2008; 9:1171-1178.
86. Sutterwala FS, Ogura Y, Szczepanik M, et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006; 24:317-327.
87. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007; 14:10-22.
88. Scott AM, Saleh M. The inflammatory caspases: guardians against infections and sepsis. Cell Death Differ 2007; 14:23-31.
89. Joshi VD, Kalvakolanu DV, Hebel JR, et al. Role of caspase 1 in murine antibacterial host defenses and lethal endotoxemia. Infect Immun 2002; 70:6896-903.
90. Sarkar A, Hall MW, Exline M, et al. Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis independently of interleukin-1beta and interleukin-18. Am J Respir Crit Care Med 2006; 174:1003-10.
91. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011; 29:707-35.
92. Saleh M, Vaillancourt JP, Graham RK, et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004; 429:75-9.
93. Saleh M, Mathison JC, Wolinski MK, et al. Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 2006; 440:1064-8.
94. Fahy RJ, Exline MC, Gavrilin MA, et al. Inflammasome mRNA expression in human monocytes during early septic shock. Am J Respir Crit Care Med 2008; 177:983-8.
95. Yin Y, Yan Y, Jiang X, et al. Inflammasomes are differentially expressed in cardiovascular and other tissues. Int J Immunopathol Pharmacol 2009; 22:311-22.
96. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 2004; 5:730-737.
97. Kang DC, Gopalkrishnan RV, Wu Q, et al. mda-5: An interferoninducible putative RNA helicase with double-stranded RNAdependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci USA 2002; 99:637-642.
98. Barbalat R, Ewald SE, Mouchess ML, Barton GM. Nucleic acid recognition by the innate immune system. Annu Rev Immunol 2011; 29:185-214.
99. Yoneyama M, Fujita T. RIG-I family RNA helicases: cytoplasmic sensor for antiviral innate immunity 6. Cytokine Growth Factor Rev 2007; 18:545-551.
100. Luo D, Ding SC, Vela A, et al. Structural insights into RNA recognition by RIG-I. Cell 2011; 147:409-22.
101. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005; 122:669-682.
102. Xu LG, Wang YY, Han KJ, et al. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 2005; 19:727-740.
103. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437:1167-1172.
104. Loo YM, Gale M, Jr. Immune signaling by RIG-I-like receptors. Immunity 2011; 34:680-92.
105. Calandra T, Bochud PY, Heumann D. Cytokines in septic shock. Curr Clin Top Infect Dis 2002; 22:1-23.
106. Bozza FA, Salluh JI, Japiassu AM, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007; 11:R49.
107. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8:32-43.
108. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003; 2:391-405.
109. Fisher CJ, Jr., Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-702.
110. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011; 34:149-62.
111. Flierl MA, Rittirsch D, Gao H, et al. Adverse functions of IL-17A in experimental sepsis. FASEB J 2008; 22:2198-205.
112. Freitas A, Alves-Filho JC, Victoni T, et al. IL-17 receptor signaling is required to control polymicrobial sepsis. J Immunol 2009; 182:7846-54.
113. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10:103-10.
114. Alves-Filho JC, Sonego F, Souto FO, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 2010; 16:708-12.
115. Roger T, Calandra T. Interleukin-33 safeguards neutrophils in sepsis. Nat Med 2010; 16:638-9.
116. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179:1895-1902.
117. Bacher M, Metz CN, Calandra T, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996; 93:7849-7854.
118. Bernhagen J, Calandra T, Mitchell RA, et al. MIF is a pituitaryderived cytokine that potentiates lethal endotoxaemia. Nature 1993; 365:756-759.
119. Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003; 197:1467-1476.
120. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13:587-596.
121. Shi X, Leng L, Wang T, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006; 25:595-606.
122. Roger T, David J, Glauser MP, Calandra T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001; 414:920-924.
123. Mitchell RA, Liao H, Chesney J, et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 2002; 99:345-350.
124. Nguyen MT, Lue H, Kleemann R, et al. The cytokine macrophage migration inhibitory factor reduces pro-oxidative stress-induced apoptosis. J Immunol 2003; 170:3337-3347.
125. Kleemann R, Hausser A, Geiger G, et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000; 408:211-216.
126. Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoidinduced modulator of cytokine production 49. Nature 1995; 377:68-71.
127. Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1 2. Eur J Immunol 2005; 35:3405-3413.
128. Emonts M, Sweep FC, Grebenchtchikov N, et al. Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 2007; 44:1321-1328.
129. Bozza FA, Gomes RN, Japiassu AM, et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004; 22:309-313.
130. Renner P, Roger T, Bochud PY, et al. A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. FASEB J 2011.
131. Sprong T, Pickkers P, Geurts-Moespot A, et al. Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia. Shock 2007; 27:482-487.
132. Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6:164-170.
133. Bacher M, Meinhardt A, Lan HY, et al. Migration inhibitory factor expression in experimentally induced endotoxemia. Am. J. Pathol. 1997; 150:235-246.
134. Al-Abed Y, Dabideen D, Aljabari B, et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 2005; 280:36541-36544.
135. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29:139-62.
136. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-51.
137. Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosismediated sepsis lethality. J Exp Med 2006; 203:1637-42.
138. van Zoelen MA, Yang H, Florquin S, et al. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009; 31:280-4.
139. Youn JH, Oh YJ, Kim ES, et al. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharidemediated TNF-alpha production in human monocytes. J Immunol 2008; 180:5067-74.
140. Chavakis T, Bierhaus A, Al-Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198:1507-15.
141. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005; 33:564-73.
142. Karlsson S, Pettila V, Tenhunen J, et al. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 2008; 34:1046-53.
143. Mitola S, Belleri M, Urbinati C, et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 2006; 176:12-5.
144. Liliensiek B, Weigand MA, Bierhaus A, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113:1641-50.
145. Lutterloh EC, Opal SM, Pittman DD, et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007; 11:R122.
146. Osorio F, Reis e Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 2011; 34:651-64.
147. Drickamer K. Two distinct classes of carbohydrate-recognition domains in animal lectins. J Biol Chem 1988; 263:9557-60.
148. Zelensky AN, Gready JE. The C-type lectin-like domain superfamily. FEBS J 2005; 272:6179-217.
149. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502.
150. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009; 9:465-79.
151. Kerrigan AM, Brown GD. Syk-coupled C-type lectin receptors that mediate cellular activation via single tyrosine based activation motifs. Immunol Rev 2010; 234:335-52.
152. Drummond RA, Saijo S, Iwakura Y, Brown GD. The role of Syk/CARD9 coupled C-type lectins in antifungal immunity. Eur J Immunol 2011; 41:276-81.
153. Taylor PR, Tsoni SV, Willment JA, et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol 2007; 8:31-8.
154. Werner JL, Metz AE, Horn D, et al. Requisite role for the dectin-1 beta-glucan receptor in pulmonary defense against Aspergillus fumigatus. J Immunol 2009; 182:4938-46.
155. Gringhuis SI, den Dunnen J, Litjens M, et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nat Immunol 2009; 10:203-13.
156. Drummond RA, Brown GD. The role of Dectin-1 in the host defence against fungal infections. Curr Opin Microbiol 2011; 14:392-9.
157. Goodridge HS, Underhill DM. Fungal Recognition by TLR2 and Dectin-1. Handb Exp Pharmacol 2008:87-109.
158. Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361:1760-7.
159. LeibundGut-Landmann S, Gross O, Robinson MJ, et al. Syk-and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007; 8:630-8.
160. Saijo S, Ikeda S, Yamabe K, et al. Dectin-2 recognition of alphamannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity 2010; 32:681-91.
161. Robinson MJ, Osorio F, Rosas M, et al. Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J Exp Med 2009; 206:2037-51.
162. Gazi U, Martinez-Pomares L. Influence of the mannose receptor in host immune responses. Immunobiology 2009; 214:554-61.
163. van de Veerdonk FL, Marijnissen RJ, Kullberg BJ, et al. The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe 2009; 5:329-40.
164. Yamasaki S, Matsumoto M, Takeuchi O, et al. C-type lectin Mincle is an activating receptor for pathogenic fungus, Malassezia. Proc Natl Acad Sci USA 2009; 106:1897-902.
165. Svajger U, Anderluh M, Jeras M, Obermajer N. C-type lectin DCSIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity. Cell Signal 2010; 22:1397-405.
166. Mukhopadhyay S, Pluddemann A, Gordon S. Macrophage pattern recognition receptors in immunity, homeostasis and self tolerance. Adv Exp Med Biol 2009; 653:1-14.
167. Pluddemann A, Neyen C, Gordon S. Macrophage scavenger receptors and host-derived ligands. Methods 2007; 43:207-17.
168. Pluddemann A, Hoe JC, Makepeace K, et al. The macrophage scavenger receptor A is host-protective in experimental meningococcal septicaemia. PLoS Pathog 2009; 5:e1000297.
169. Haworth R, Platt N, Keshav S, et al. The macrophage scavenger receptor type A is expressed by activated macrophages and protects the host against lethal endotoxic shock. J Exp Med 1997; 186:1431-9.
170. Guo L, Song Z, Li M, et al. Scavenger Receptor BI Protects against Septic Death through Its Role in Modulating Inflammatory Response. J Biol Chem 2009; 284:19826-34.
171. Cai L, Ji A, de Beer FC, et al. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest 2008; 118:364-75.
172. Sarrias MR, Farnos M, Mota R, et al. CD6 binds to pathogenassociated molecular patterns and protects from LPS-induced septic shock. Proc Natl Acad Sci USA 2007; 104:11724-9.